A Dose-Escalating Phase I Study for Safety and Tolerability of Bevacizumab in Collagen Delivery Vehicle Administered Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum Tolerated Dose of bevacizumab (Avastin) following local administration.
John Abrahams, MD
Brain & Spine Surgeons of New York
United States: Institutional Review Board
|Brain & Spine Surgeons of New York||White Plains, New York 10604|